NIP292
/ China Resources Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 24, 2023
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
(clinicaltrials.gov)
- P1 | N=56 | Completed | Sponsor: The National Institutes of Pharmaceutical R&D Co. Ltd, China | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Jul 2022
Trial completion • Trial completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
April 07, 2022
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: The National Institutes of Pharmaceutical R&D Co. Ltd, China | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Aug 2022
Trial completion date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
January 22, 2021
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
(clinicaltrials.gov)
- P1; N=72; Recruiting; Sponsor: The National Institutes of Pharmaceutical R&D Co. Ltd, China
Clinical • New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases
1 to 3
Of
3
Go to page
1